Lobbyists have been hired. Patient advocate organizations alerted. Bill sponsors found. The only question that remains is whether bio-pharma can convince Congress to abandon its longstanding policy position opposing Medicare reimbursement for obesity drugs. Meanwhile, in the backroom the insurance industry is engaged in hand-to-hand combat with bureaucrats to ensure the lawyers don't redefine obesity as a chronic disease.
It is certainly a clash of the titans so we will do what we can to demystify the process and the possibilities. Please join us.
|
Wednesday, December 13th @ 10am ET (Add to Outlook Calendar) Connection Details: https://app.hedgeye.com/feed_items/143401?with_category=48-health-policy Format:45 min w/ Q & A |
Let me know if you have any questions in the meantime.
Emily Evans
Managing Director – Health Policy
X
LinkedIn
Calendly Meeting Set-up
